Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
What is Hangzhou Tigermed Consulting stock price today?▼
The current price of HNGZY is $4.45 USD — it has increased by +11.25% in the past 24 hours. Watch Hangzhou Tigermed Consulting stock price performance more closely on the chart.
What is Hangzhou Tigermed Consulting stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Hangzhou Tigermed Consulting stocks are traded under the ticker HNGZY.
Is Hangzhou Tigermed Consulting stock price growing?▼
HNGZY stock has risen by +0% compared to the previous week, the month change is a +11.25% rise, over the last year Hangzhou Tigermed Consulting has showed a +11.25% increase.
What is Hangzhou Tigermed Consulting market cap?▼
Today Hangzhou Tigermed Consulting has the market capitalization of 3.83B
When is the next Hangzhou Tigermed Consulting earnings date?▼
Hangzhou Tigermed Consulting is going to release the next earnings report on August 29, 2026.
What were Hangzhou Tigermed Consulting earnings last quarter?▼
HNGZY earnings for the last quarter are 0.01 USD per share, whereas the estimation was 0.04 USD resulting in a -77.21% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Hangzhou Tigermed Consulting revenue for the last year?▼
Hangzhou Tigermed Consulting revenue for the last year amounts to 936.7M USD.
What is Hangzhou Tigermed Consulting net income for the last year?▼
HNGZY net income for the last year is 123.76M USD.
Does Hangzhou Tigermed Consulting pay dividends?▼
Yes, HNGZY dividends are paid annual. The last dividend per share was 0.04 USD. As of today, Dividend Yield (FWD)% is 0.41%.
How many employees does Hangzhou Tigermed Consulting have?▼
As of July 16, 2026, the company has 11,130 employees.
In which sector is Hangzhou Tigermed Consulting located?▼
Hangzhou Tigermed Consulting operates in the Health & Wellness sector.
When did Hangzhou Tigermed Consulting complete a stock split?▼
Hangzhou Tigermed Consulting has not had any recent stock splits.
Where is Hangzhou Tigermed Consulting headquartered?▼
Hangzhou Tigermed Consulting is headquartered in Hangzhou, United States.